D.E. Shaw & Co’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.94M Buy
12,600
+4,400
+54% +$1.3M ﹤0.01% 2658
2026
Q2
$2.59M Buy
8,200
+1,600
+24% +$377K ﹤0.01% 2978
2026
Q1
$1.32M Sell
6,600
-1,000
-13% -$198K ﹤0.01% 3231
2025
Q4
$1.44M Buy
7,600
+6,000
+375% +$1.15M ﹤0.01% 3296
2025
Q3
$283K Buy
+1,600
New +$238K ﹤0.01% 4140
2021
Q3
– Sell
-16,030
Closed -$1.31M – 5092
2021
Q2
$1.31M Hold
16,030
– – ﹤0.01% 3324
2021
Q1
$1.52M Buy
+16,030
New +$1.52M ﹤0.01% 2806
2019
Q4
– Sell
-58,510
Closed -$3.63M – 4072
2019
Q3
$3.63M Sell
58,510
-32,060
-35% -$2.01M ﹤0.01% 1882
2019
Q2
$6.45M Buy
90,570
+82,876
+1,077% +$6.1M 0.01% 1423
2019
Q1
$603K Sell
7,694
-11,061
-59% -$838K ﹤0.01% 2898
2018
Q4
$1.59M Sell
18,755
-28,373
-60% -$3.02M ﹤0.01% 2345
2018
Q3
$8.07M Buy
47,128
+18,755
+66% +$2.83M 0.01% 1239
2018
Q2
$3.67M Buy
28,373
+12,343
+77% +$1.38M ﹤0.01% 1753
2018
Q1
$1.65M Hold
16,030
– – ﹤0.01% 2175
2017
Q4
$1.37M Buy
+16,030
New +$1.39M ﹤0.01% 2391
2017
Q1
– Sell
-16,030
Closed -$1.02M – 3457
2016
Q4
$1.02M Buy
+16,030
New +$1.01M ﹤0.01% 2449
2016
Q1
– Sell
-9,939
Closed -$672K – 3625
2015
Q4
$672K Hold
9,939
– – ﹤0.01% 2896
2015
Q3
$531K Buy
+9,939
New +$603K ﹤0.01% 3022
2014
Q3
– Sell
-16,030
Closed -$623K – 4257
2014
Q2
$623K Sell
16,030
-42,319
-73% -$1.72M ﹤0.01% 3340
2014
Q1
$2.45M Buy
58,349
+49,372
+550% +$2.06M ﹤0.01% 2188
2013
Q4
$295K Sell
8,977
-33,342
-79% -$1.09M ﹤0.01% 4068
2013
Q3
$1.14M Sell
42,319
-13,946
-25% -$392K ﹤0.01% 2909
2013
Q2
$1.31M Buy
+56,265
New +$1.01M ﹤0.01% 2486

Other funds holding LGND

D.E. Shaw & Co's LGND Position: Q3 2026 in Review

D.E. Shaw & Co increased its Ligand Pharmaceuticals (LGND) stake by 11% in Q3 2026, buying an estimated $1.77M and bringing the position to 62,505 shares worth $19.5M. The position accounts for 0.01% of the portfolio, ranked #1321.

D.E. Shaw & Co first reported a position in LGND in Q2 2013 and has held it in 38 quarters since. The position peaked at $22.9M in Q4 2018. 431 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • D.E. Shaw & Co held 62,505 shares of Ligand Pharmaceuticals worth $19.5M as of Q3 2026.
  • D.E. Shaw & Co bought 5,990 Ligand Pharmaceuticals shares in Q3 2026, an estimated $1.77M.
  • Ligand Pharmaceuticals made up 0.01% of D.E. Shaw & Co's portfolio in Q3 2026, its #1321 holding.
  • D.E. Shaw & Co first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 38 quarters since.
  • D.E. Shaw & Co's Ligand Pharmaceuticals position peaked at $22.9M in Q4 2018.
  • 431 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.